Litcius/Paper detail

Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome

Joanna Zurko, Bryon D. Johnson, Emilie Aschenbrenner, Timothy S. Fenske, Mehdi Hamadani, Parameswaran Hari, Nirav N. Shah

2022JAMA Oncology40 citationsDOIOpen Access PDF

Abstract

This case series describes the use of early intrathecal steroid administration to manage high-grade and steroid-refractory immune effector cell-associated neurotoxicity syndrome among patients with B-cell non-Hodgkin lymphoma.

Topics & Concepts

MedicineNeurotoxicityEffectorImmune systemLymphomaIntrathecalImmunologyOncologyInternal medicineToxicitySurgeryCAR-T cell therapy researchCancer Treatment and PharmacologyNeuroblastoma Research and Treatments
Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome | Litcius